224 related articles for article (PubMed ID: 26497557)
1. Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.
Sohlberg E; Pfefferle A; Andersson S; Baumann BC; Hellström-Lindberg E; Malmberg KJ
Oncotarget; 2015 Oct; 6(33):34178-90. PubMed ID: 26497557
[TBL] [Abstract][Full Text] [Related]
2. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.
Yalniz FF; Daver N; Rezvani K; Kornblau S; Ohanian M; Borthakur G; DiNardo CD; Konopleva M; Burger J; Gasior Y; Pierce S; Kantarjian H; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):658-663.e2. PubMed ID: 30001986
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.
Tsirogianni M; Grigoriou E; Kapsimalli V; Dagla K; Stamouli M; Gkirkas K; Konsta E; Karagiannidou A; Gkodopoulos K; Stavroulaki G; Pappa V; Angelopoulou M; Lowdell M; Tsirigotis P
Leuk Lymphoma; 2019 Oct; 60(10):2457-2463. PubMed ID: 30947589
[TBL] [Abstract][Full Text] [Related]
5. Demethylating treatment suppresses natural killer cell cytolytic activity.
Gao XN; Lin J; Wang LL; Yu L
Mol Immunol; 2009 Jun; 46(10):2064-70. PubMed ID: 19394699
[TBL] [Abstract][Full Text] [Related]
6. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
[TBL] [Abstract][Full Text] [Related]
8. Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance.
Manser AR; Uhrberg M
Cancer Immunol Immunother; 2016 Apr; 65(4):417-26. PubMed ID: 26288343
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
Adès L; Itzykson R; Fenaux P
Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
[TBL] [Abstract][Full Text] [Related]
10. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V
Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation.
Boy M; Bisio V; Zhao LP; Guidez F; Schell B; Lereclus E; Henry G; Villemonteix J; Rodrigues-Lima F; Gagne K; Retiere C; Larcher L; Kim R; Clappier E; Sebert M; Mekinian A; Fain O; Caignard A; Espeli M; Balabanian K; Toubert A; Fenaux P; Ades L; Dulphy N
Nat Commun; 2023 Feb; 14(1):588. PubMed ID: 36737440
[TBL] [Abstract][Full Text] [Related]
13. [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome].
Mi H; Fu R; Wang H; Qu W; Ruan E; Wang X; Wang G; Liu H; Wu Y; Song J; Xing L; Guan J; Li L; Jiang H; Zhang W; Yue L; Shao Z
Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):737-41. PubMed ID: 24844955
[TBL] [Abstract][Full Text] [Related]
14. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Papageorgiou SG; Kontos CK; Kotsianidis I; Vasilatou D; Symeonidis A; Galanopoulos A; Bouchla A; Hatzimichael E; Repousis P; Zikos P; Viniou NA; Poulakidas E; Vassilakopoulos TP; Diamantopoulos P; Diamantopoulos MA; Mparmparousi D; Bouronikou E; Papadaki H; Panayiotidis P; Pappa V
Hematol Oncol; 2018 Oct; 36(4):693-700. PubMed ID: 30129144
[TBL] [Abstract][Full Text] [Related]
15. Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience.
Papoutselis M; Douvali E; Papadopoulos V; Spanoudakis E; Margaritis D; Tsatalas C; Kotsianidis I
Leuk Res; 2014 Feb; 38(2):161-5. PubMed ID: 24239174
[TBL] [Abstract][Full Text] [Related]
16. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
[TBL] [Abstract][Full Text] [Related]
17. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
18. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
Guo KY; Mei JZ; Yao KT
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
[TBL] [Abstract][Full Text] [Related]
19. Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors.
Hasenkamp J; Borgerding A; Uhrberg M; Falk C; Chapuy B; Wulf G; Jung W; Trümper L; Glass B
Scand J Immunol; 2008 Mar; 67(3):218-29. PubMed ID: 18226015
[TBL] [Abstract][Full Text] [Related]
20. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
Front Immunol; 2021; 12():665541. PubMed ID: 33986753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]